^
Association details:
| Biomarker: | IFNG gene signature |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumor mutation burden (TMB), PD-L1, IFN-? signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Published date:
09/30/2019
Excerpt:
CP1108/NCT01693562 was a nonrandomized phase I/II trial including 201 2L UC pts who were treated with D (10 mg/kg Q2W)...IFNGS significantly correlated with better PFS in CP1108 (HR = 0.5, p = 0.02).
DOI:
10.1093/annonc/mdz253